Navigation Links
Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results
Date:11/14/2011

placed on clinical hold by the Food and Drug Administration, or FDA; (iv) patients enrolled in the Company's Neo-Urinary Conduit clinical trial will not experience additional adverse events, which could delay clinical trials or cause the Company to terminate the development of the Neo-Urinary Conduit; (v) the results of the clinical trial for the Neo-Urinary Conduit will support further development of that product candidate; (vi) data from the Company's ongoing preclinical studies will continue to be supportive of advancing its preclinical product candidates; and (vii) the Company will be able to progress its product candidates that are undergoing preclinical testing, including the Neo-Kidney Augment, into clinical trials and (viii) the Company will be able to obtain the capital it needs to develop its product candidates and continue its operations. For additional factors which could cause actual results to differ from expectations, reference is made to the reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward looking statements in this release are made only as of the date hereof and the Company disclaims any intention or responsibility for updating predictions or expectations in this release.TENGION, INC.
(A Development-Stage Company)CONDENSED STATEMENTS OF OPERATIONS(unaudited)Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Period fromJuly 10,2003(inception)throughSeptember30, 20112010201120102011Operating expenses:Research and development$

3,543$

2,837$

10,112$

9,579$

114,143General and administrative1,5021,3834,3845,19739,899Depreciation1,2157183,6612,81622,827Other expense—26—995995Total operating expenses(6,260)(4,964)(18,157)(18,587)(177,864)Interest income201247398,498Interest expense(476)(193)(1,737)(666)(14,706)Change in fair value of warrant liability—4,18519214,12316,185Net loss $

(6
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Tengion Appoints Scott Flora to Board of Directors
2. Tengion Appoints Diane Jorkasky, M.D., to its Board of Directors
3. Tengion Provides Update on Neo-Urinary Conduit Clinical Trial
4. Tengion Announces FDA Orphan-Drug Designation for Neo-Urinary Conduit
5. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
6. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
7. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
10. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
11. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... the list of stocks featured in the Analyst Blog. Every ... and events impacting stocks and the financial markets. Stocks recently ... Free Report ), Gilead (Nasdaq: GILD - Free Report ... AbbVie (NYSE: ABBV - Free Report ) and Celgene ... Zacks is promoting its ,Buy, stock recommendations. Get #1Stock ...
(Date:7/31/2014)... 2014 For the first time, cardiac surgeons, ... of the SynCardia temporary Total Artificial Heart in a ... on the Journal of Visualized Experiments website. ... on the SynCardia Total Artificial Heart implantation   ... of the SynCardia Total Artificial Heart," a July 18, ...
(Date:7/31/2014)... , July 31, 2014 Astellas has ... of corporate and employee communications in the Americas ... Winton , senior vice president, chief communications officer. ... developing and leading corporate brand initiatives and reputation ... North and South America . ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... Development of Intradigm,s ICS-283, PALO ALTO, ... developer of targeted, systemic RNA interference (RNAi),therapeutics, ... company,s,TargeTran(TM) delivery system is capable of delivering ... RNAs (siRNAs) that suppress,tumor-induced angiogenesis by silencing ...
... BiPar Sciences, Inc., a,privately held biopharmaceutical ... demonstrating that BSI-401 inhibited pancreatic cancer,cell growth ... and in combination with,oxaliplatin. BSI-401 is BiPar,s ... therapies known as PARP (poly-ADP-ribose polymerase) inhibitors. ...
Cached Medicine Technology:Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice 2Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice 3BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor 2
(Date:7/31/2014)... (PRWEB) July 31, 2014 Insight Accelerator ... a Series A round of investment for $4.6 million ... device for collecting vital signs. The company joined ... technology to fruition with the help of Insight development ... our reason for launching the Accelerator,” says Steve McPhilliamy, ...
(Date:7/31/2014)... FL (PRWEB) July 31, 2014 Women ... to take charge of their financial future. The ... women, has opened registration for 6 upcoming Los Angeles ... women, for women, and with input from Kim Kiyosaki, ... and It’s Rising Time) who is passionate about women’s ...
(Date:7/31/2014)... New York (PRWEB) July 31, 2014 ... Ethicon, Inc. continue to move forward in the federal ... of West Virginia, Bernstein Liebhard LLP reports. According to ... scheduled to consider certain defense motions now pending before ... the U.S. Magistrate Judge on Tuesday, August 5th at ...
(Date:7/31/2014)... New York (PRWEB) July 31, 2014 ... grow, as Bernstein Liebhard LLP notes that Johnson ... it plans to voluntarily remove its power morcellators ... a report from Bloomberg.com, the company said it ... benefits associated with the devices remain uncertain.* , ...
(Date:7/31/2014)... Ticket Down is a reliable ... Sporting Goods Park in suburban Denver on Tuesday, September ... team has found a second home competing on American soil. ... playing international friendly games and will look to have another ... Park in Commerce City, Colorado. The match will be Mexico’s ...
Breaking Medicine News(10 mins):Health News:Insight Accelerator Labs Advances Member Toward Commercialization 2Health News:Insight Accelerator Labs Advances Member Toward Commercialization 3Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2Health News:Ethicon Transvaginal Mesh Lawsuits Move Forward, With Scheduling of Hearing in Federal Litigation, Bernstein Liebhard LLP Reports 2Health News:Ethicon Transvaginal Mesh Lawsuits Move Forward, With Scheduling of Hearing in Federal Litigation, Bernstein Liebhard LLP Reports 3Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 2Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 3
... New food safety laws are to be introduced in Hong ... China, officials announced Thursday.// ,The measures will allow the ... sale if there are concerns, the territory's minister for health ... over fish and eggs imported into Hong Kong from China ...
... average around ?106,000 in the initial one year following ... and social care depict an increase in the average ... ,Ministers and NHS Bigwigs are mighty unhappy that huge ... them for improving the quality of healthcare services. However, ...
... that one in three cases of mentally ill patients ... after studying the statistics relating to hospitalization and patient ... those mentally ill patients readmitted, 45 percent of patients ... cent of people with schizophrenia and one in five ...
... of Medical Research, the data from Population Based Cancer ... the age specific// incidence rates of breast cancer below ... scheme of National Cancer Control Programme (NCCP), special emphasis ... by creating awareness. Grant-in-aid is provided to Non-Governmental Organisations ...
... in treatment of cancer, are likely to harm normal ... the Journal of Biology.// ,The study observed that ... be long lasting. This study gives a clue to ... that are seen in lots of cancer patients. Cancer ...
... Texas surgeons lead robotically assisted laparoscopic surgeries. A ... places in the body. Laparoscopic surgeons at// UT ... gastric-bypass and colon-resections surgeries. , Laparoscopic ... than one long incision. This usually results in ...
Cached Medicine News:Health News:Hong Kong to Tighten Food Safety Laws 2Health News:Mentally-Ill Patients Get Re-Hospitalized More 2Health News:North Texas Surgeons Lead Robotically Assisted Laparoscopic Surgeries. 2
... Tegagel hydrogel wound filler and Tegagel ... amorphous hydrogel dressings specially formulated to ... has been shown to enhance wound ... meets clinical needs for management of ...
... and Tegagel hydrogel wound filler with ... formulated to help provide a moist ... enhance wound healing. The unique, viscous, ... management of non-draining, minimally draining and ...
... a complete physician preference card system as ... for all the supply management requirements of ... system combined with a broad array of ... cart and operating suite supply and charge ...
... Esteem™ External Vacuum Therapy System restores sexual ... men. Non-invasive and low cost vacuum therapy, ... desirable outcome", makes it the ideal therapy ... Therapy System causes penile rigidity that can ...
Medicine Products: